# Summary of #hplusroadmap IRC Log (July 12, 2014)

* A scientific paper about neurological effects was shared via paperbot (http://informahealthcare.com/doi/abs/10.3109/00207454.2011.558225), though the conversation about its content didn't develop further.

* Discussion about high-cost pharmaceuticals was sparked by an article about Gilead Sciences being questioned by senators regarding the high cost of their Hepatitis C drug (http://www.techtimes.com/articles/10272/20140711/senators-ask-gilead-sciences-to-explain-itself-high-cost-of-hep-c-drug.htm).

* Participants debated whether pharmaceutical companies settle with families of patients who die due to lack of access to expensive medications, with some questioning why there aren't more news stories about deaths from inaccessibility of treatments.

* The case of Bianca Scott was mentioned, who needed the extremely expensive drug Soliris (eculizumab), a humanized monoclonal antibody, highlighting the issue of rare disease treatments and their funding through government programs.

* Technical discussion about the feasibility of creating black market pharmaceuticals ensued, with participants analyzing the costs and challenges of reproducing complex drugs like monoclonal antibodies, estimating that production costs would be significantly lower than market prices.